MNPR
Monopar Therapeutics
Latest Form 4:Purchase$105KbyVu Quan Anh (Chief Financial Officer) · filed Dec 29, 2025
Monopar Therapeutics (MNPR) has 11 SEC Form 4 filings (19 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Jul 2, 2026.
- Industry:Biotechnology
- CEO:Chandler D. Robinson
- Employees:22
- HQ:Wilmette, IL, US
- IPO:2019-12-19
Insider Buying
$105K
reported purchases (SEC code P)
Insider Selling
$344K
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
Market Cap
$757.3M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Vu Quan AnhFirst filing | Chief Financial Officer | Purchase | 1,500 | $105K | Dec 29 | SEC ↗ |
KLAUSNER ARTHUR JFirst filing | Director | Sale | 5,121 | $344K | Dec 19 | SEC ↗ |
Related companies
Monopar Therapeutics is in the Healthcare sector.